Myomo (NYSEAMERICAN:MYO) is a medical robotics company specializing in powered orthotic devices designed to restore movement to individuals with upper limb paralysis and neuromuscular disorders. The company’s flagship product, the MyoPro®, is a wearable robotic brace that uses proprietary sensors and actuators to detect and amplify a patient’s own muscle signals. By translating faint electrical impulses into movement, Myomo’s technology enables users to perform everyday tasks such as eating, writing and self-care activities independently.
Beyond its core hardware offering, Myomo provides a comprehensive support structure that includes device customization, clinical training and ongoing patient monitoring. The company works closely with medical professionals, including occupational therapists and neurologists, to integrate the MyoPro® into personalized treatment plans. Myomo also leverages telehealth platforms to deliver remote guidance and progress tracking, ensuring continuity of care and optimizing therapeutic outcomes.
Founded in 2006 as a spin-out from Rensselaer Polytechnic Institute, Myomo went public in 2018 and is headquartered in Cambridge, Massachusetts. Under the leadership of CEO Paul Gudonis, the organization has expanded its management team and strategic advisory board, bringing together experts in robotics, rehabilitation and healthcare operations. This multidisciplinary approach has guided the company’s product development and commercialization efforts.
Myomo markets its devices throughout the United States via a growing network of certified distributors and clinical partners, with additional channels in Canada and select European markets. As it continues investing in research and development, the company aims to broaden its technology portfolio and explore applications in lower-limb mobility and other areas of rehabilitation robotics.
